Logo Logo
Switch Language to German
Jacobson, Caron; Kopp, Nadja; Layer, Jacob V.; Redd, Robert A.; Tschuri, Sebastian; Haebe, Sarah; Bodegom, Diederik van; Bird, Liat; Christie, Amanda L.; Christodoulou, Alexandra; Saur, Amy; Tivey, Trevor; Zapf, Stefanie; Bararia, Deepak; Zimber-Strobl, Ursula; Rodig, Scott J.; Weigert, Oliver; Weinstock, David M. (2016): HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. In: Blood, Vol. 128, No. 21: pp. 2517-2526
Full text not available from 'Open Access LMU'.


The Bruton tyrosine kinase (BTK) inhibitor ibrutinib induces responses in 70% of patients with relapsed and refractory mantle cell lymphoma (MCL). Intrinsic resistance can occur through activation of the nonclassical NF-kappa B pathway and acquired resistance may involve the BTKC481S mutation. Outcomes after ibrutinib failure are dismal, indicating an unmet medical need. We reasoned that newer heat shock protein 90 (HSP90) inhibitors could overcome ibrutinib resistance by targeting multiple oncogenic pathways in MCL. HSP90 inhibition induced the complete degradation of both BTK and I kappa B kinase a in MCL lines and CD40-dependent B cells, with downstream loss of MAPK and nonclassical NF-kappa B signaling. A proteome-wide analysis in MCL lines and an MCL patient-derived xenograft identified a restricted set of targets from HSP90 inhibition that were enriched for factors involved in B-cell receptor and JAK/STAT signaling, the nonclassical NF-kappa B pathway, cell-cycle regulation, and DNA repair. Finally, multiple HSP90 inhibitors potently killed MCL lines in vitro, and the clinical agent AUY922 was active in vivo against both patient-derived and cell-line xenografts. Together, these findings define the HSP90-dependent proteome in MCL. Considering the disappointing clinical activity of HSP90 inhibitors in other contexts, trials in patients with MCL will be essential for defining the efficacy of and mechanisms of resistance after ibrutinib failure.